Long-term effects of alogliptin benzoate in hemodialysis patients with diabetes: A 2-year study

Nephron - Clinical Practice

Volumn 123, Issue 1-2, 2013, Pages 46-51

  Nakamura, Yuya ^a   Inagaki, Masahiro ^a   Shimizu, Tatsuo ^a   Fujita, Kiichiro ^a   Inoue, Michiyasu ^a   Gotoh, Hiromichi ^a   Oguchi, Katsuji ^a   Goto, Yoshikazu ^a  

^a SHOWA UNIVERSITY   (Japan)

Author keywords

Active glucagon like peptide 1; Alogliptin benzoate; Diabetes; DPP 4 inhibitor; Hemodialysis

Indexed keywords

ALBUMIN; ALOGLIPTIN; C PEPTIDE; CHOLESTEROL; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; GLYCOSYLATED ALBUMIN; HEMOGLOBIN; HEMOGLOBIN A1C; INSULIN; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; PIPERIDINE DERIVATIVE; URACIL;

ADULT; ARTICLE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DIET; DRUG EFFECT; DRUG EFFICACY; EXERCISE; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMODIALYSIS PATIENT; HUMAN; HYPOGLYCEMIA; IMMUNOREACTIVITY; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; TREATMENT DURATION; ALBUMIN BLOOD LEVEL; CLINICAL TRIAL; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HORMONE BLOOD LEVEL; INSULIN BLOOD LEVEL; LONG TERM CARE; MAINTENANCE THERAPY; ANALOGS AND DERIVATIVES; COMORBIDITY; DIABETES MELLITUS, TYPE 2; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; JAPAN; LONGITUDINAL STUDY; MIDDLE AGED; PREVALENCE; RENAL INSUFFICIENCY, CHRONIC; RENAL REPLACEMENT THERAPY; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

COMORBIDITY; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; JAPAN; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PIPERIDINES; PREVALENCE; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; TREATMENT OUTCOME; URACIL;

EID: 84878925607     PISSN: None     EISSN: 16602110     Source Type: Journal    
DOI: 10.1159/000351678     Document Type: Article

References (25)

1. Shima K, Komatsu M, Kawahara K, Minaguchi J, Kawashima S: Stringent glycaemic control prolongs survival in diabetic patients with end-stage renal disease on haemodialysis. Nephrology (Carlton) 2010; 15: 632-638.
2. Ishimura E, Okuno S, Kono K, Fujino-Kato Y, Maeno Y, Kagitani S, Tsuboniwa N, Nagasue K, Maekawa K, Yamakawa T, Inaba M, Nishizawa Y: Glycemic control and survival of diabetic hemodialysis patients-importance of lower hemoglobin A1C levels. Diabetes Res Clin Pract 2009; 83: 320-326.
3. Abbatecola AM, Maggi S, Paolisso G: New approaches to treating type 2 diabetes mellitus in the elderly: role of incretin therapies. Drug Aging 2008; 25: 913-925.
4. Williams-Herman D, Round E, Swern AS, Musser B, Davies MJ, Stein PP, Kaufman KD, Amatruda JM: Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis. BMC Endocr Disord 2008; 8: 14.
5. Talsania T, Anini Y, Siu S, Drucker DJ, Brubaker PL: Peripheral exendin-4 and peptide YY(3-36) synergistically reduce food intake through different mechanisms in mice. Endocrinology 2005; 146: 3748-3756.
6. Nyström T, Gutniak MK, Zhang Q, Zhang F, Holst JJ, Ahrén B, Sjöholm A: Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 2004; 287:E1209-E1215.
7. Johansen OE, Neubacher D, von Eynatten M, Patel S, Woerle HJ: Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme. Cardiovasc Diabetol 2012; 11: 3.
8. Noyan-Ashraf MH, Momen MA, Ban K, Sadi AM, Zhou YQ, Riazi AM, Baggio LL, Henkelman RM, Husain M, Drucker DJ: GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 2009; 58: 975-983.
9. Mannucci E, Ognibene A, Cremasco F, Bardini G, Mencucci A, Pierazzuoli E, Ciani S, Messeri G, Rotella CM: Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects. Diabetes Care 2001; 24: 489-494.
10. Williams-Herman D, Johnson J, Teng R, Golm G, Kaufman KD, Goldstein BJ, Amatruda JM: Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes Obes Metab 2010; 12: 442-451.
11. Rosenstock J, Niggli M, Maldonado-Lutomirsky M: Long-term 2-year safety and efficacy of vildagliptin compared with rosiglitazone in drug-naïve patients with type 2 diabetes mellitus. Diabetes Obes Metab 2009; 11: 571-578.
12. Göke B, Hershon K, Kerr D, Calle Pascual A, Schweizer A, Foley J, Shao Q, Dejager S: Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin. Horm Metab Res 2008; 40: 892-895.
13. Kikuchi M, Abe N, Kato M, Terao S, Mimori N, Tachibana H: Vildagliptin dose-dependently improves glycemic control in Japanese patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2009; 83: 233-240.
14. Nonaka K, Kakikawa T, Sato A, Okuyama K, Fujimoto G, Kato N, Suzuki H, Hirayama Y, Ahmed T, Davies MJ, Stein PP: Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 2008; 79: 291-298.
15. Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE; Sitagliptin Study 021 Group: Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006;29:2632-2637.
16. DeFronzo RA, Fleck PR, Wilson CA, Mekki Q; Alogliptin Study 010 Group: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study. Diabetes Care 2008; 31: 2315-2317.
17. Balas B, Baig MR, Watson C, Dunning BE, Ligueros-Saylan M, Wang Y, He YL, Darland C, Holst JJ, Deacon CF, Cusi K, Mari A, Foley JE, DeFronzo RA: The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. J Clin Endocrinol Metab 2007; 92: 1249-1255.
18. Raz I, Hanefeld M, Xu L, Caria C, Williams-Herman D, Khatami H; Sitagliptin Study 023 Group: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006; 49: 2564-2571.
19. Ahrén B, Landin-Olsson M, Jansson PA, Svensson M, Holmes D, Schweizer A: Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 2004; 89: 2078-2084.
20. Lee B, Shi L, Kassel DB, Asakawa T, Takeuchi K, Christopher RJ: Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys. Eur J Pharmacol 2008; 589: 306-314.
21. Inzucchi SE: Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 2002; 287: 360-372.
22. Vilsbøll T, Krarup T, Deacon CF, Madsbad S, Holst JJ: Reduced postprandial concentrations of intact biologically active glucagonlike peptide 1 in type 2 diabetic patients. Diabetes 2001; 50: 609-613.
23. Toft-Nielsen MB, Damholt MB, Madsbad S, Hilsted LM, Hughes TE, Michelsen BK, Holst JJ: Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 2001; 86: 3717-3723.
24. Nauck M, Stöckmann F, Ebert R, Creutzfeldt W: Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986; 29: 46-52.
25. Yabe D, Kuroe A, Lee S, Koin W, Hyo T, Hishizawa M, Kurose T, Deacon CF, Holst JJ, Hirano T, Inagaki N, Seino Y: Little enhancement of meal-induced glucagons-like peptide 1 secretion in Japanese: comparison of type 2 diabetes patients and healthy controls. J Diabetes Invest 2010; 1: 56-59.